European equities traded in the US as American depositary receipts were slightly higher late Thursday morning, rising 0.12% to 1,505.82 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical companies Grifols (GRFS) and Genfit (GNFT), which rose 2% and 1.8% respectively. They were followed by biopharmaceutical company argenx (ARGX) and pharmaceutical company Novo Nordisk (NVO), which increased 1.4% and 0.4% respectively.
The decliners from continental Europe were led by 3D printer company Materialise (MTLS) and semiconductor company Sequans Communications (SQNS), which fell 10.7% and 2.7% respectively. They were followed by oil and gas company TotalEnergies (TTE) and telecommunications company Nokia (NOK), which were down 2.6% and 1.2% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and telecommunications operator Vodafone Group (VOD), which climbed 13.3% and 3% respectively. They were followed by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and NuCana (NCNA), which were up 2.6% and 0.2% respectively.
The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Mereo BioPharma Group (MREO), which dropped 4.6% and 4% respectively. They were followed by software firm Endava (DAVA) and cruise line operator Carnival (CUK), which lost 2% and 1.9% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.